GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Earnings per Share (Diluted)

Luye Pharma Group (HKSE:02186) Earnings per Share (Diluted) : HK$0.16 (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Earnings per Share (Diluted)?

Luye Pharma Group's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$0.11. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.16.

Luye Pharma Group's EPS (Basic) for the six months ended in Dec. 2023 was HK$0.11. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.16.

Luye Pharma Group's EPS without NRI for the six months ended in Dec. 2023 was HK$0.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.12.

During the past 12 months, Luye Pharma Group's average EPS without NRIGrowth Rate was -39.50% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -25.40% per year.

During the past 13 years, Luye Pharma Group's highest 3-Year average EPS without NRI Growth Rate was 42.20% per year. The lowest was -29.20% per year. And the median was 2.10% per year.


Luye Pharma Group Earnings per Share (Diluted) Historical Data

The historical data trend for Luye Pharma Group's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Earnings per Share (Diluted) Chart

Luye Pharma Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.26 -0.05 0.19 0.16

Luye Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 0.10 0.10 0.04 0.11

Competitive Comparison of Luye Pharma Group's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luye Pharma Group's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's PE Ratio falls into.



Luye Pharma Group Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Luye Pharma Group's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(582.552-0)/3728.363
=0.16

Luye Pharma Group's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(418.51-0)/3762.223
=0.11

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Luye Pharma Group  (HKSE:02186) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Luye Pharma Group Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Luye Pharma Group (HKSE:02186) Business Description

Traded in Other Exchanges
Address
No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Liu Dianbo 2301 Trustee
Luye Life Sciences Group Ltd 2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd. 2201 Interest of corporation controlled by you
Nelumbo Investments Limited 2201 Interest of corporation controlled by you
Shorea Lbg 2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd. 2101 Beneficial owner
Ginkgo (ptc) Limited 2301 Trustee
Luye Pharmaceutical International Co., Ltd. 2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Hillhouse Nev Holdings Limited 2101 Beneficial owner
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hillhouse Fund V, L.p. 2201 Interest of corporation controlled by you
Xin Ye Sheng Wu Yi Yao Kong Gu You Xian Gong Si
Yang Yu Fen

Luye Pharma Group (HKSE:02186) Headlines

No Headlines